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importance of the T-stage and have 
reanalyzed our primary data. By analy-
sis of variance and the Wilcoxon rank 
sum test, we show that the distribution 
of maximum standardized uptake value 
(SUV
max
) within the three “T” groups 
(T1a/T1b/T2a) is significantly different 
(p < 0.0001).
Cox proportional hazards model 
was then used to assess the relation-
ship between T-stage and survival with 
and without adjustment for SUV
max
 
(uncategorized). After adjustment for 
T-stage, the effect of SUV
max
 remains 
statistically significant (p = 0.003). 
In our study, the effect of T-stage was 
not a statistically significant predic-
tor of survival with or without adjust-
ment for SUV
max
. The lack of statistical 
significance for T-stage does not neces-
sarily imply that the variable does not 
have prognostic importance. Rather, the 
power of this statistical analysis may be 
limited by there being only 134 deaths, 
which in general drives the power of a 
study to detect a clinically meaningful 
effect.
As we suggested, prospective 
treatment trials in early-stage dis-
ease could incorporate SUV
max
 to 
stratify patients for therapy, although 
we acknowledge that other fea-
tures including T-stage need to be 
considered.
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Reply to 
“Prognostic Value of 
Fluorodeoxyglucose-
Positron Emission 
Tomography”
To the Editor:
I read with interest the elegant study 
by Kwon et al1 in which the authors dem-
onstrated a significant correlation between 
survival and fluorodeoxyglucose (FDG) 
uptake on positron emission tomogra-
phy in stage I non–small-cell lung can-
cer (NSCLC) patients. However, I found 
it surprising that tumor size, as reflected 
in the “T” classification (e.g., T1 versus 
T2a, or T1a versus T1b versus T2a), was 
not taken into account in the multivariate 
analysis of potential prognostic factors.
In the Discussion section,1 among 
their study limitations, the authors cor-
rectly mention the fact that FDG uptake 
can be underestimated in small tumors 
(e.g., <2 cm) because of “volume aver-
aging effects inherent in positron emis-
sion tomography.” However, they fail to 
infer that this limitation could explain 
in part (if not all) their findings. I note 
that 36% of the study population (122 
out of 336 patients) had T1aN0 tumors, 
and 40% of the study population (134 
patients) had T2aN0 tumors.
Therefore, I wonder if the prog-
nostic value attributed to FDG uptake 
could be in fact a mere tumor size effect 
as, by definition, tumor size reflected 
in the T classification is a strong and 
well-characterized prognostic factor in 
early-stage NSCLC.2 Could the authors 
provide their study results after intro-
ducing the T classification in the mul-
tivariate analysis, and/or explain why 
they chose not to do so? Without such 
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an analysis and positive results, I would 
remain reluctant to accept FDG uptake 
as an “independent” (statistically speak-
ing) prognostic factor for survival in 
stage I NSCLC patients from this study.
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In Response
We appreciate Dr. Girard’s com-
ments about our recent study in the 
Journal of Thoracic Oncology on flu-
orodeoxyglucose-positron emission 
tomography in patients with early-
stage lung cancer.1 We recognize the 
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